A detailed history of Allspring Global Investments Holdings, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 100,382 shares of BMRN stock, worth $6.69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
100,382
Previous 100,258 0.12%
Holding current value
$6.69 Million
Previous $8.25 Million 14.53%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$69.02 - $93.84 $8,558 - $11,636
124 Added 0.12%
100,382 $7.06 Million
Q2 2024

Jul 26, 2024

SELL
$74.43 - $92.22 $1,563 - $1,936
-21 Reduced 0.02%
100,258 $8.25 Million
Q1 2024

Apr 18, 2024

BUY
$83.81 - $99.0 $3.33 Million - $3.93 Million
39,708 Added 65.56%
100,279 $8.76 Million
Q4 2023

Jan 25, 2024

BUY
$76.22 - $98.51 $4.55 Million - $5.89 Million
59,760 Added 7368.68%
60,571 $5.84 Million
Q3 2023

Oct 27, 2023

BUY
$85.07 - $94.48 $68,991 - $76,623
811 New
811 $71,000
Q2 2023

Jul 18, 2023

SELL
$86.68 - $100.3 $37.9 Million - $43.9 Million
-437,747 Reduced 93.8%
28,940 $2.51 Million
Q1 2023

Apr 13, 2023

BUY
$87.74 - $117.27 $3.01 Million - $4.02 Million
34,286 Added 7.93%
466,687 $45.4 Million
Q4 2022

Jan 23, 2023

BUY
$80.93 - $108.63 $34.6 Million - $46.4 Million
427,438 Added 8612.49%
432,401 $0
Q3 2022

Oct 26, 2022

SELL
$82.16 - $96.94 $172,453 - $203,477
-2,099 Reduced 29.72%
4,963 $420,000
Q2 2022

Jul 25, 2022

SELL
$71.48 - $86.85 $1.28 Million - $1.55 Million
-17,898 Reduced 71.71%
7,062 $584,000
Q1 2022

May 02, 2022

BUY
$74.28 - $92.69 $330,620 - $412,563
4,451 Added 21.7%
24,960 $1.92 Million
Q4 2021

Jan 28, 2022

BUY
$71.72 - $91.47 $1.47 Million - $1.88 Million
20,509 New
20,509 $1.81 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.